AMERICAN SOCIETY OF CLINICAL ONCOLOGY

As filed

Subsection

03

NTEE code

G9XC

Classification

2800

Street

2318 MILL RD STE 800

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Other organizations at this address

2 other organizations in the IRS Business Master File list the same street address. matched by us

This address is a suite or unit (STE 800). Organizations that share one are often clients of the same office-services firm, accountant or registered agent rather than related to each other.

We match the street line and ZIP code as the IRS gives them, ignoring case and outer spaces and nothing else, so "AVE" and "AVENUE" count as different streets and this list can miss some. A shared address can mean related organizations or a shared office, but it can also be a registered agent, a mail drop or a service provider holding mail for unrelated clients. It is not, by itself, evidence that two organizations are connected.

• ASCO ASSOCIATION

  EIN 83-3561693

• CONQUER CANCER FDN OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  EIN 31-1667995

Mission and programs · 2024

• SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:ASCO'S MEETING PORTFOLIO DELIVERS, TO ASCO'S CORE AUDIENCE OF HEALTH PROFESSIONALS, THE SCIENCE AND EDUCATION CRITICAL TO IMPROVING PATIENT CARE AND CLINICAL PRACTICE BY HOSTING CONFERENCES THAT BRING TOGETHER FACULTY AND PRACTITIONERS BOTH IN-PERSON AND ONLINE. IN 2024, ASCO'S PREMIER ANNUAL MEETING, THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 36,400 PROFESSIONALS, INCLUDING OVER 14,400 PROFESSIONALS FROM 140 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, ASCO BREAKTHROUGH, AND THE BEST OF ASCO MEETING, A FURTHER 10,400 PROFESSIONALS, OVER 4,100 OF WHOM WERE OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED.

  Expenses $70,800,952 · Grants $5,283,009 · Revenue $109,069,704

• SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS "(CENTRA)" LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) STUDY, WHICH IS A PRECISION MEDICINE BASKET TRIAL THAT INVESTIGATES THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED NEARLY 3,000 PATIENTS SINCE IT OPENED IN 2016. TAPUR CONTINUES TO PUBLISH TRIAL RESULTS IN PEER-REVIEWED CLINICAL CANCER RESEARCH JOURNALS AND PRESENT RESULTS AT CLINICAL CANCER RESEARCH CONFERENCES; (2) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (3) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH ASSESSES AND REPORTS ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US; (4) ASCO'S WORK IN IMPROVING ACCESS TO CLINICAL TRIALS THROUGH TRAINING FOR SITES; AND (5) A PATIENT-CENTERED CLINICAL TRIAL, THE CDK4/6 INHIBITOR DOSING STUDY, WHICH OPENED TO ENROLLMENT IN DECEMBER 2024 AND EVALUATES STANDARD VS. TITRATED DOSING APPROACHES FOR PATIENTS AGE 65 AND OLDER WITH HR+/HER2- METASTATIC BREAST CANCER. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.

  Expenses $9,374,885 · Revenue $4,963,700

• SEE SCHEDULE O:QUALITY OF CARE INITIATIVES:QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI) IS A QUALITY SELF-ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 263 PRATICES PARTICAPTED IN 2024. QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS ON THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. 290 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2024.GUIDELINES. ASCO'S GUIDELINES PROGRAM ENGAGES WITH MORE THAN 1,000 ASCO MEMBER VOLUNTEERS, ON A YEARLY BASIS, TO DEVELOP EXPERT RECOMMENDATIONS AND STANDARDS DESIGNED TO PROMOTE CONSISTENT, SAFE DELIVERY OF HIGH-QUALITY CANCER CARE WORLDWIDE. CLINICAL CONTENT IS DISSEMINATED USING PUBLISHED ARTICLES, RECOMMENDATION TABLES, ALGORITHMS, PODCASTS, VISUAL ABSTRACTS, AND OTHER RESOURCES ACCESSIBLE THROUGH ASCO JOURNALS, THE ASCO WEBSITE, AND THE ASCO GUIDELINES APP. GUIDELINES ARE AMONG THE MOST READ ARTICLES IN THE JOURNAL OF CLINICAL ONCOLOGY (JCO), WITH OVER 1.1 MILLION DOWNLOADS AND 503 CITATIONS IN 2024. ASCO PUBLISHES BETWEEN 25 AND 30 NEW OR UPDATED GUIDELINES EACH YEAR, WITH A GROWING LIBRARY OF GUIDELINE SUMMARIES THAT HAVE BEEN TRANSLATED INTO SPANISH. A TOTAL OF 39 GUIDELINE PRODUCTS WERE PUBLISHED IN THE JCO FAMILY OF JOURNALS IN 2024, INCLUDING SEVERAL RAPID RECOMMENDATIONS AND MULTIPLE ITERATIONS OF ASCO'S COMPREHENSIVE LIVING GUIDELINE THAT ADDRESSES THE CARE OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER.

  Expenses $9,146,436 · Grants $8,000 · Revenue $1,452,853

• POLICY:IN COLLABORATION WITH VOLUNTEER EXPERTS, ASCO WORKS TO ADDRESS A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. POLICY IS CONVEYED IN FORMAL STATEMENTS PUBLISHED IN ASCO JOURNALS, AND IN PUBLIC FACING COMMUNICATIONS CHANNELS. AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, INSURANCE ISSUES, COST, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2024, ASCO CONTINUED TO DRAW PUBLIC ATTENTION TO THE PERSISTENT CRISIS OF DRUG SHORTAGES, THE ONGOING AND WORSENING HARMS RELATED TO AGGRESSIVE UTILIZATION MANAGEMENT PRACTICES, THE NEED TO SUSTAIN ACCESS TO EVIDENCE BASED CANCER CARE, THE NEED TO BALANCE BENEFITS/HARMS ASSOCIATED WITH USE OF ARTIFICIAL INTELLIGENCE IN CANCER CARE, AND THE IMPORTANCE OF TELEMEDICINE AS A COMPONENT OF HEALTH CARE DELIVERY.CENTER FOR GLOBAL IMPACT (CGI):ASCO'S INTERNATIONAL AFFAIRS DEPARTMENT HAS TRANSITIONED TO THE CENTER FOR GLOBAL IMPACT (CGI). CGI PARTNERS ACROSS ASCO AND ONCOLOGY COMMUNITIES WORLDWIDE TO INTEGRATE GLOBAL PERSPECTIVES INTO ASCO STRATEGIES AND OPERATIONS, AND TO CATALYZE AND ADVANCE ASCO'S GLOBAL IMPACT GOALS AS DIRECTED BY THE SOCIETY'S MISSION, VISION, AND STRATEGIC PLANS. CGI SERVES AS A RESOURCE ACROSS ASCO FOR GLOBAL ISSUES RELEVANT TO ASCO, WITH A PARTICULAR EMPHASIS ON VOLUNTEER ENGAGEMENT, DIPLOMACY, STRATEGIC PLANNING, PROGRAM DELIVERY, AND GLOBAL OPERATIONS. EXAMPLES OF OPERATIONS ARE AS FOLLOWS:- JOINT SESSIONS- INTERNATIONAL CANCER CORPS- INTERNATIONAL COURSES- INTERNATIONAL DEVELOPMENT AND EDUCATION AWARD (IDEA)SCIENTIFIC PUBLICATIONS:ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- JCO ONCOLOGY ADVANCES (JCO OA)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.EDUCATION AND PROFESSIONAL DEVELOPMENT:IN 2024, ASCO LAUNCHED THE INAUGURAL LEADERSHIP DEVELOPMENT PROGRAM (LDP): LATIN AMERICA CLASS OF 12, CREATING A NETWORK OF PHYSICIAN LEADERS TO ADVANCE CANCER CARE. IN 2024, ASCO HAD RECORD VIRTUAL MENTORING PROGRAM PARTICIPATION (68% INCREASE), RESULTING IN THE CREATION OF A TECHNOLOGICAL SOLUTION TO MEET THE DEMAND. THE IN-TRAINING EXAM FOR ONCOLOGY FELLOWS HAD RECORD PARTICIPATION WITH 2333 TRAINEES FROM 20 COUNTRIES ACROSS THE GLOBE PARTICIPATING. ALL PROGRAMS SERVE THE PURPOSE OF BUILDING THE WORKFORCE.

  Expenses $20,299,067 · Grants $72,500 · Revenue $22,149,676

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2024

  Revenue

  $159,100,585

  Expenses

  $143,670,256

  Contributions

  $7,681,674

  Grants paid

  $5,363,509

• 2023

  Revenue

  $174,337,293

  Expenses

  $155,488,043

  Contributions

  $16,259,283

  Grants paid

  $4,632,496

• 2022

  Revenue

  $146,139,860

  Expenses

  $144,269,886

  Contributions

  $9,250,760

  Grants paid

  $4,042,358

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2024 · 990-T

  Revenue

  — not reported

  Expenses

  — not reported

  Assets (EOY)

  — not reported

• 2023 · 990-T

  Revenue

  — not reported

  Expenses

  — not reported

  Assets (EOY)

  — not reported

• 2022 · 990-T

  Revenue

  — not reported

  Expenses

  — not reported

  Assets (EOY)

  — not reported

• 2021 · 990

  Revenue

  $107,588,628

  Expenses

  $119,778,637

  Assets (EOY)

  $283,820,689

• 2021 · 990-T

  Revenue

  — not reported

  Expenses

  — not reported

  Assets (EOY)

  — not reported

• 2020 · 990

  Revenue

  $138,374,082

  Expenses

  $134,735,801

  Assets (EOY)

  $279,249,289

• 2020 · 990-T

  Revenue

  — not reported

  Expenses

  — not reported

  Assets (EOY)

  — not reported

• 2019 · 990

  Revenue

  $162,711,421

  Expenses

  $148,108,869

  Assets (EOY)

  $269,484,782

• 2018 · 990

  Revenue

  $159,884,094

  Expenses

  $145,806,474

  Assets (EOY)

  $227,652,015

• 2017 · 990

  Revenue

  $144,538,521

  Expenses

  $136,560,852

  Assets (EOY)

  $228,266,590

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

• CONQUER CANCER FOUNDATION OF ASCO

  $3,770,000

  2024 · CONTRIBUTION

• CONQUER CANCER FOUNDATION OF ASCO

  $3,652,500

  2023 · CONTRIBUTION

• CONQUER CANCER FOUNDATION OF ASCO

  $3,514,500

  2022 · CONTRIBUTION

• UNIVERSITY OF PENNSYLVANIA

  $195,000

  2024 · CANCER RESEARCH & EDUCATION

• UNIVERSITY OF CALIFORNIA SAN FRANCISCO

  $169,872

  2024 · CONTRIBUTION

• CINCINNATI CANCER FOUNDATION INC

  $152,500

  2024 · CONTRIBUTION

• UNIVERSITY OF CHICAGO

  $130,000

  2022 · CONTRIBUTION

• YALE UNIVERSITY

  $130,000

  2023 · CONTRIBUTION

• YALE UNIVERSITY

  $115,833

  2022 · CONTRIBUTION

• UNIVERSITY OF PENNSYLVANIA

  $109,167

  2023 · CANCER RESEARCH & EDUCATION

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

• CONQUER CANCER FDN OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  $9,233,468

  2022 · CHARITABLE ASSISTANCE

• CONQUER CANCER FDN OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  $7,804,140

  2023 · CHARITABLE ASSISTANCE

• CONQUER CANCER FDN OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

  $7,681,670

  2024 · CHARITABLE ASSISTANCE

• COUNCIL OF MEDICAL SPECIALTY SOCIETIES

  $1,665,820

  2023 · Diagnostic Excellence Research Project with Deliverables

• COUNCIL OF MEDICAL SPECIALTY SOCIETIES

  $126,811

  2022 · Sub-recipient

• DONOR ADVISED CHARITABLE GIVING

  $10,000

  2022 · HEALTH

• DONOR ADVISED CHARITABLE GIVING

  $6,100

  2024 · HEALTH

• DONOR ADVISED CHARITABLE GIVING

  $5,600

  2023 · HEALTH

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Taxable family

From Schedule R Parts I, III and IV: entities that legally are the filer, and taxable partnerships, corporations and trusts it is related to. These record ownership and control, not shared board members or money.

Other IRS files